Yazan Abuodeh, MD
Radiation Oncology · Salina, KSNPI 1265873905
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.5% of the total across 31 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 20.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $363, 6.1 times the $59 reported in 2019. That places this record below the midpoint for radiation oncology clinicians in KS, where the typical reported total is $776.
Across 31 payments — averaging $25.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Reflexion Medical, Inc.$156
- Boston Scientific$77
- AstraZeneca$75
- Siemens Medical Solutions USA, Inc.$57
- Novocure Inc.$33
- Stemline Therapeutics Inc.$30
- plus $348 from 17 others
What the payments were for
- Food & beverage$76498%
- Education$122%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$776 in reported general payments places this provider in the 50th percentile of 54 radiation oncology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 149 | $763 |
| Oxycodone Hcl | 31 | $564 |
| Oxybutynin Chloride ErOxybutynin Chloride | 30 | $473 |
| Dexamethasone | 31 | $454 |
| Megestrol Acetate | 17 | $136 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Salina
- Ronald ChenKansas City$31K
- Xinglei ShenKansas City$16K
- David BryantWichita$15K
- Mark ThompsonOverland Park$9K
- David AkhavanKansas City$9K
- Fen WangKansas City$7K
- Joshua WeirWichita$6K
- Vickie MasseyOverland Park$5K
- Gregory GanKansas City$5K
- Ronny RotondoKansas City$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.